FDA NDC Directory · JSON-LD · Markdown

Flucelvax

NDC 70461-656 · VACCINE · INJECTION, SUSPENSION

Generic nameINFLUENZA A VIRUS A/Tasmania/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Tasmania/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Arizona/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INAC
Labeler / ManufacturerSeqirus Inc.
Marketing categoryBiologic License Application · App BLA125408
Dosage form / routeINJECTION, SUSPENSION · INTRAMUSCULAR
Active ingredientsINFLUENZA A VIRUS A/TASMANIA/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) (15 ug/.5mL)
INFLUENZA A VIRUS A/TASMANIA/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) (15 ug/.5mL)
INFLUENZA B VIRUS - B/ARIZONA/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) (15 ug/.5mL)
Marketing started20260701
Marketing ended20270731
Package count1

External sources

Source: openFDA. Public-domain (CC0).